Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Healthy Adult

In brief

This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers

Key facts

Study ID

NCT07499908

Run by

Citryll BV

People needed

10

Starts

2026-05-31

Expected to finish

2026-10-31

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men or women, 18 to 75 years of age (inclusive) at screening.

You may not qualify if…

• Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the trial, or that would pose an unacceptable risk to the participant in the opinion of the Investigator.

Where it is running

• ICON — Groningen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.